This presentation forcuses on the impact of medications on urologic clinical conditions, including drugs recently approved by the FDA, drugs with updated clinical evidence demonstrating urologic effects, and drugs with urologic concerns in specific patient populations.

Contact hours available until 4/7/2020.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.

Conferences Committee Disclosures:
• Donna L. Thompson, MSN, CRNP, FNP-BC, CCCN-AP - Advisor Board for Domtar Industries
• Carolyn Stahlhut, CRNP - husband is employed as a contractor through Kelly Scientific at Jansen Pharmaceutical, also listed as a sub investigator for several clinical trials

Speakers Conflict of Interest Disclosure: There are no disclosures to declare.

Commercial Support and Sponsorship: There are no disclosures to delcare.

Accreditation Statement:
The Society of Urologic Nurses and Associates (SUNA) is accredited as a provider of continuing nursing education by the American Nurses’ Credentialing Center’s Commission on Accreditation.

The SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.

Learning Outcome:
At the conclusion of this activity, the learner will be able to select appropriate medications for patients with urologic complications based on indication, anticipation side effects, concerns specific to high-risk patient populations.

Laura H. Waite PharmD, BCPS, CLS, BC-ADM

Appearances